Trevi Therapeutics
- Biotech or pharma, therapeutic R&D
Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a late-stage respiratory biotech company focused on becoming the leader across chronic cough conditions with Haduvio (oral nalbuphine ER). Across chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) indications, Trevi has shown a large magnitude of effect, broad response, and rapid onset (within 1 week) supporting its best-in-class and/or first-in-class potential. Trevi is focused on chronic cough categories with a significant unmet medical need and no FDA-approved therapies, and through a unique KAMA mechanism, Haduvio has $5B+ peak sales potential with a specialty commercial model and pricing. Trevi looks forward to the expected results of the Ph2b trial in patients with IPF chronic cough in the upcoming weeks (2Q 2025).
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}